Este website é destinado para o público portugués. Para que você verifique se o website de seu país está disponpivel, selecione o seu país da lista.
Fechar
Fechar
Fechar
Fechar
Fechar
Fechar

O nosso portfolio diversificado reforça o nosso compromisso com a Saúde das Mulheres

Fechar

Novidades da Theramex

Fechar

Contacte-nos

Fechar

Carreiras

14 April 2022

Theramex UK Stock Update

Theramex is pleased to advise that the full range of Evorel® (estradiol or estradiol/norethisterone) patches are currently in stock across the UK and we do not expect any stock issues based on current levels of demand.

Thanks to the incredible work of healthcare professionals and menopause activists, more women are informed about their menopause and the options available to them, and therefore there has been a significantly greater level of demand over the past year for HRT. Most women in the UK now use transdermal HRT patches, as a result we have increased capacity at all stages of production to meet this demand and ensure people can continue to access our products. 

We are working closely with Government and relevant partners to ensure the continued supply of our products and anticipate any future increases in demand. While HRT stock issues continue in other sectors of the market, we recommend people work with their clinician to understand availability of various products, suitable alternatives and appropriate prescription intervals to enable companies to best manage supply.

17 June 2022

Theramex Announces European Commission Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for the treatment of symptoms of Uterine Fibroids

Ler mais

28 March 2022

A consortium of Carlyle and PAI Partners to acquire Theramex from CVC Funds

Ler mais